Fig. 5
Aβ1–42 is directly bonded to SCARB2. a SH-SY5Y, Vero, and RD cells were pretreated with Aβ1–42 (20 µg/mL) or pirodavir (40 µM) at 4 °C for 60 min, followed by EV-A71 infection (MOI = 2.5) at 4 °C for another 1 h. The overall RNA was harvested, and EV-A71 VP1 RNA variation was evaluated by qRT-PCR. b SH-SY5Y cells were subjected to CVA16 or CVB3 infection (MOI = 1) and afterward subjected to Aβ1–42 peptide or RBV treatment (20 µg/mL) for 24 h. The virus VP1 RNA level was analyzed by qRT-PCR. c Vero cells were subjected to SCARB2-myc or pcDNA 3.1 + plasmid transfection for 24 h and lysed with protein lysate containing phosphatase and protease inhibitor. Subsequently, the lysis buffer supernatant was mixed with Aβ1–42 immobilized magnetic beads at 4 °C for 2 h. The bound beads were suspended with a 1 × sample loading buffer and boiled for 10 min. The binding of SCARB2 was detected by WB assay with anti-SCARB2 antibody